Objective To observe the effects and toxicity of nimotuzumab combined paclitaxel and carboplatin in the treatment of advanced non small cell lung cancer .Methods 168 cases of patients with advanced non-small cell lung cancer were randomly divided into study group and control group ,with 84 cases in each group .Study group was treated with nimotuzumab 200 mg ,1 times per week ,for 6 weeks ,two weeks later the patients were treated with 200 mg and stopped when the disease progressed ,paclitaxel lipo-some(135 mg/m2 ,iv drip 3 h ,1 days) ,carboplatin(300 mg/m2 ,iv drip ,1 days);the control group was given paclitaxel liposome(135 mg/m2 ,iv drip 3 h ,1 days) ,carboplatin(300 mg/m2 ,iv drip ,1 days) ,21 days for 1 cycle .Results Study group RR 38 .1% (32/84);control group RR 23 .8% (20/84)(P<0 .05) .The main side effects of two groups of were gastrointestinal reaction and bone marrow suppression ,there were 64 cases of above Ⅱ digestive tract reaction in the study group ,accounting for 76 .2% ,52 cases ofⅡ degrees of bone marrow suppression ,accounting for 61 .9% ,52 cases of Ⅱ degrees of alopecia ,accounting for 61 .9% ;54 cases of control group Ⅱ digestive tract reaction ,accounting for 66 .7% ,54 cases of Ⅱ degrees of bone marrow suppression ,accounting for 66 .7% ,and 58 cases of Ⅱ degrees of alopecia ,accounted for 57 .1% (P>0 .05) .In the study group ,progression-free survival period was 7 .8 months ,the median survival period was 14 .2 months;in the control group ,progression-free survival period was 5 .1 months ,the median survival period was 9 .8 months(P<0 .05) .Conclusion nimotuzumab combined paclitaxel and carboplatin in the treatment of advanced non small cell lung cancer has good clinical curative effect ,and would not increase adverse reactions .It is worthy of clinical application .

We used the Brucella data in Xinjiang between year 2009 to 2010 to explore and analyze the spatial clustering fea‐tures of brucellosis in Xinjiang ,and provided the basis for prevention and control on brucellosis in Xinjiang ,China .The time and population distribution of brucellosis in Xinjiang was analyzed for statistical analysis with descriptive epidemiology .Mean‐while ,we also used quartile classification methods to map the incidence of brucellosis in Xinjiang spatial distribution ,and calcu‐lated the Global Moran’s I index on the spatial clustering analysis .Results showed that brucellosis in Xinjiang had obvious sea‐sonal differences (peaked in May‐September) ,more cases for male than that for female (gender ratio‐‐2 .96∶1) ,and the total incidence of 74% were farmer and herdsman ,mainly concentrated at th e age of 40 to 60 years old .Compared with the onset range of brucellosis in 2009 ,there were clear tendency to spread in 2010 .The Global Moran’s I index was 0 .116 4 (P=0 .017) ,showing the spatial clustering on the incidence of brucellosis in Xinjiang .The incidence of hot spots concentrated in Tacheng and Altay ,and the incidence of cold spots concentrated in Kashi .The incidence level brucellosis has significant spatial aggregation in the area of Xinjiang ,which should be strengthened the prevention and control of high‐risk areas .

OBJECTIVETo evaluate the bioequivalence of orally disintegrating tablets of pentoxyverine citrate (tested preparation) in healthy male volunteers.

METHODSA single oral dose of the tested and reference preparations at 25 mg were given to 20 healthy volunteers in a randomized two-period cross-over design. Plasma pentoxyverine citrate concentrations were determined by HPLC-MS/ESI+ method. The pharmacokinetic parameters were calculated and the bioequivalence of the two preparations were evaluated using DAS program.

RESULTSThe Tmax, Cmax, AUC0 15 and AUC0infinity of tested and reference preparations were 1.62-/+0.75 h and 2.52-/+1.21 h, 62.28-/+33.06 microg/L and 59.72-/+33.25 microg/L, 234.44-/+130.01 microg.h.L(-1) and 228.77-/+129.24 microg.h.L(-1), 246.80-/+136.19 microg.h.L(-1) and 244.11-/+140.73 microg.h.L(-1), respectively. The 90% confidence interval of C(max), AUC0 15 and AUC0infinity of tested preparations were 81.4%-138.4%, 86.0%-123.3% and 86.5%-121.2%, respectively.

CONCLUSIONThe tested and reference preparations are bioequivalent.

Adult ; Area Under Curve ; Biological Availability ; Citric Acid ; administration & dosage ; pharmacokinetics ; Cross-Over Studies ; Cyclopentanes ; administration & dosage ; pharmacokinetics ; Humans ; Male ; Tablets ; Therapeutic Equivalency ; Young Adult